SUMMARY
Addressing glaucoma and corneal disease can present substantial difficulties, often necessitating medical therapy as the primary mode of treatment. Polypharmacy is prevalent among patients with glaucoma; half of patients with newly diagnosed glaucoma initially require more than one medication to control IOP, and a further 30% require add-on treatment after one year. Theand ROCKET-1 andtrials ROCKET-2 netarsudil was as effective in reducing in patients with a baseline IOPa showed that netarsudil wasasastimolol effective as timololthe in IOP reducing the IOP in patients with of and amp;lt;25 mmHg it is important note that . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.